Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report
This case highlights the differential effects of upadacitinib and abrocitinib, possibly due to their distinct JAK2 inhibition profiles. The findings underscore the importance of considering kinase selectivity when using JAK inhibitors in patients with overlapping immune-mediated skin disorders.
Authors
- Yonghu Sun (ORCID: https://orcid.org/0000-0003-4553-2871)
- Zhaoyang Wang (ORCID: https://orcid.org/0000-0003-0898-4801)
- Meng Wang (ORCID: https://orcid.org/0009-0007-2747-5697)
Institutions
- Academy of Medical Sciences (GB)
- Shandong Provincial Institute of Dermatology and Venereology (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1080/09546634.2025.2528344
- Citations
- 2
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 2.30
Funders
- National Natural Science Foundation of China